Looks like the NK platform will become one of the main focus points for CHM and IMU as well as IMU recently took ALA's iNKT platform under its wings.
The speed of how technologies get updated these days is mind blowing compared to past decades, just the duration of human trials hasn't changed at all. Time for regulators to adjust their time consuming guide lines or at least to increase staff to get those new technologies faster in to trials and to patients if successful.
GLTA
Ann: Sponsored Research Agreement to advance CORE-NK portfolio, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |